Lung administration of antibiotics by nebulization is promising for improving treatment efficiency for pulmonary infections, as it increases drug concentration at sites of infection while minimizing systemic side effects. For poorly soluble molecules like rifampicin, cyclodextrins (CD) may improve lung delivery by permitting higher dosing. For this purpose, we investigated rifampicin-CD complex...

SETTING A Mycobacteriology Reference Laboratory in Johannesburg, South Africa. OBJECTIVE To determine the ability of FASTPlaqueTB-RIF, a rapid bacteriophage-based test, to correctly identify rifampicin susceptibility in clinical strains of Mycobacterium tuberculosis after growth in the Bactec 460 semi-automated liquid culture system. DESIGN A comparative study of FASTPlaqueTB-RIF and conven...

Rifampicin, one of the primary tuberculosis drugs, is a PGP substrate that is encoded by MDR 1 gene. The objectives of the research was to study the impacts of MDR1 gene polymorphism toward plasma rifampicin levels in Javanese patients with pulmonary tuberculosis. The subjects of this research are Javanese tuberculosis patients treated by fixed dosage combination (FDC) of anti-tuberculosis drug...

Although high-dose rifampicin holds promise for improving tuberculosis control by potentially shortening treatment duration, these effects attributed to eradication of persistent bacteria are unclear. The presence of persistent Mycobacterium tuberculosis was examined using resuscitation promoting factors (RPFs) in both in vitro hypoxia and in vivo murine tuberculosis models before and after tre...

Introduction: One of the main reasons for the development of the resistance in the therapy for Tuberculosis is the mono drug therapy. This may be due to the drug-drug interactions as the therapy includes combination of various drugs leading to poor bioavailability of these drugs. One such reported interaction is between Rifampicin and Isoniazid which leads to poor bioavailability of Rifampicin....

A 2-month-old infant with Enterobacter osteomyelitis complicating total parenteral nutrition was successfully treated with rifampicin and chloramphenicol. No untoward side effects attributed to rifampicin has been noted despite prolonged administration of rifampicin.

The major clinical issue with TB therapy is the poor oral bioavailability of rifampicin in the presence of isoniazid in acidic medium. The present work was undertaken to develop a novel solid dosage form (tablet and capsule in capsule) comprising a immediate release rifampicin tablet, effervescent gastro retentive rifampicin tablet and an enteric coated isoniazid capsule that can differentiatel...

Agents inhibiting microglial activation are attracting attention as candidate drugs for neuroprotection in neurodegenerative diseases. Recently, researchers have focused on the immunosuppression induced by rifampicin. Our previous study showed that rifampicin inhibits the production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators and improves neuron survival in inflammation; howe...

Rifampicin has been proposed as a therapeutic candidate for Parkinson's disease (PD). We previously showed that rifampicin was neuroprotective in PD models in vivo and in vitro. However, the molecular mechanisms underlying are not fully elucidated. In this study, using the comprehensive proteomic analysis, we identified that the 78 kDa glucose-regulated protein (GRP78), a hallmark of the unfold...

Objective: The aim of the present study is to formulate and evaluate enteric coated pellets of Rifampicin and Isoniazid with improved Rifampicin stability in invitro conditions. Methodology: Two different capsule formulations of these drugs were prepared. Formulation-I contains immediate release uncoated pellets of Rifampicin and Isoniazid. Formulation-IIcontains immediate release enteric coate...